

UNITED STATE DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

ID

400110471011110		FIRST NAMED INVENTOR		ATTORNEY DOOVET NO
APPLICATION NO.	FILING DATE		ATTORNEY DOCKET NO.	
08/992,91	4 12/18/	97 WATANABE	Ε	0020-4348P
0022 9 2			EXAMINER	
	WART KOLAS	ZAG	ZAGHMOUT,O	
P O BOX 7		ART UNIT	PAPER NUMBER	
FALLS CHURCH VA 22040-0747			163	8 20
		•	DATE MAILED): 07/03/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED SEE ES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE		FIRST NAMED APPLICANT		ATTORNEY DOCKET NO	
08/992,914	December 18,	1997	Watanabe et al.		0020-4348P	
			1		EXAMINER	
				Ousama M-Fai		
				ART UNIT	PAPER NUMBER	
				1638	20	
			J	DATE MAILE	D:	

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

1. A reference relevant to the examination of this application may soon become available. *Ex parte* prosecution is SUSPENDED.

Inquires

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Ousama M-Faiz Zaghmout whose telephone number is (703) 308-9438. The Examiner can normally be reached Monday through Friday from 7:30 am to 5:00 pm (EST).

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Paula Hutzell, can be reached on (703) 308-4310. The fax phone number for the group is (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application should be directed to THE MATRIX CUSTOMER SERVICE CENTER whose telephone number is (703) 308-0196.

Ousama M-Faiz Zaghmout Ph.D. July 28, 1998

GARY BENZIÓN RIMARY EXAMINE Serial Number: 08/992,914 Page 2

Art Unit: 1649

...

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). A computer readable form (CRF) of the sequence listing was submitted. However, the CRF could not be processed by the Scientific and Technical Information Center (STIC) for the reason(s) set forth on the attached CRF Diskette Problem Report.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached CRF Diskette Problem Report with the reply.

Serial Number: 08/992,914

Art Unit: 1649

Future Correspondence

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Ousama M-Faiz Zaghmout whose telephone number is (703) 308-9438. The Examiner can normally be reached Monday through Friday from 7:30 am to 5:00 pm (EST).

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Douglas Robinson, can be reached on (703) 308-2897. The fax phone number for the group is (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application should be directed to THE MATRIX CUSTOMER SERVICE CENTER whose telephone number is (703) 308-0196.

Ousama M-Faiz Zaghmout Ph.D. June 29, 1998

Douglas W. Robinson
Supervisory Patent Examiner
Technology Center 1600

Application No.: 08/992,919
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of	37 C.F.R. 1.821-1.825.
Applicant's attention is directed to these regulations, published at 1114 OG 29, 18230, May 1, 1990.	May 15, 1990 and at 55 FR
2. This application does not contain, as a separate part of the disc. "Sequence	losure on paper copy, a
Listing" as required by 37 C.F.R. 1.821(c).	
3. A copy of the "Sequence Listing" in computer readable form haby 37 C.F.R. 1.821(e).	s not been submitted as required
4. A copy of the "Sequence Listing" in computer readable form ha	s been submitted. However, the
content of the computer readable form does not comply with the re and/or 1.823, as indicated on the attached copy of the market	quirements of 37 C.F.R. 1.822 I -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this applic	ation has been found to be
and/or unreadable as indicated on the attached CRF Diskette Proble computer readable form must be submitted as required by 37	m Report. A Substitute C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the	ne computer readable from of the
"Sequence Listing" as required by 37 C.F.R. 1.821(e).	•
7. Other:	
Applicant Must Provide:	
Application substitute computer readable form (CRF) copy of the	"Sequence Listing".
Apainted substitute paper copy of the "Sequence Listing", as a entry into the specification.	well as an amendment directing its
A statement that the content of the paper and computer readable applicable, include no new matter, as required by 37 C.F.R. 1.82 1.825(b) or 1.825(d).	e copies are the same and, where 1(e) or 1.821(f) or 1.821(g) or

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE